22 assets in Digestive System Neuroendocrine Neoplasm

Therapeutic assets addressing Digestive System Neuroendocrine Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Oxodotreotide Digestive System Neuroendocrine Neoplasm	National Cancer Institute (NCI)	P4	BBB (73)
L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R,R))- Digestive System Neuroendocrine Neoplasm	Novartis Pharmaceuticals	P3	BB (66)
Everolimus Digestive System Neuroendocrine Neoplasm	RayzeBio, Inc.	P3	BB (64)
Edotreotide Digestive System Neuroendocrine Neoplasm	Jiangsu HengRui Medicine Co., Ltd.	P3	B (63)
Lanreotide Digestive System Neuroendocrine Neoplasm	RayzeBio, Inc.	P3	B (60)
Regorafenib Digestive System Neuroendocrine Neoplasm	Translational Research in Oncology	P2	B (60)
Abemaciclib Digestive System Neuroendocrine Neoplasm	University of Washington	P2	CCC (53)
Domvanalimab Digestive System Neuroendocrine Neoplasm	Hospices Civils de Lyon	P2	CCC (53)
esk981 Digestive System Neuroendocrine Neoplasm	University of Michigan Rogel Cancer Center	P2	CCC (53)
Foslinanib Digestive System Neuroendocrine Neoplasm	TaiRx, Inc.	P2	CCC (53)
Ifa Digestive System Neuroendocrine Neoplasm	Roswell Park Cancer Institute	P2	CCC (53)
Nab-Sirolimus Digestive System Neuroendocrine Neoplasm	Aadi Bioscience, Inc.	P2	CCC (53)
Sargramostim Digestive System Neuroendocrine Neoplasm	Roswell Park Cancer Institute	P2	CCC (53)
Survaxm Digestive System Neuroendocrine Neoplasm	Roswell Park Cancer Institute	P2	CCC (53)
Tislelizumab Digestive System Neuroendocrine Neoplasm	Translational Research in Oncology	P2	CCC (53)
Zimberelimab Digestive System Neuroendocrine Neoplasm	Hospices Civils de Lyon	P2	CCC (53)
Cabotamig Digestive System Neuroendocrine Neoplasm	Arbele Pty Ltd	P1	CC (47)
[212pb]vmt-alpha-net Digestive System Neuroendocrine Neoplasm	National Cancer Institute (NCI)	P1	CC (43)
ryz401 Digestive System Neuroendocrine Neoplasm	RayzeBio, Inc.	P1	CC (43)
Bl-M14D1 Digestive System Neuroendocrine Neoplasm	SystImmune Inc.	P1	NR ()
Cabozantinib Digestive System Neuroendocrine Neoplasm	National Cancer Institute (NCI)	P3	NR ()